A. Barczyk (Katowice, Poland), M. Bocchino (Napoli, Na, Italy), C. Taube (Essen, Germany), H. Kerstjens (Groningen, Netherlands)
Mepolizumab in patients =3 exacerbations and eosinophil count =300 cells/µL
S. Yancey (Durham, United States of America)
|  |
Daily pattern of ß2-agonists: understanding real-life use of rescue medication
D. Stempel (Rtp, United States of America)
| |
Reslizumab for uncontrolled eosinophilic asthma in patients who experienced a single exacerbation in the previous year: sub-analysis of two phase 3 trials
M. Wechsler (Denver, United States of America)
|  |
Omalizumab decreases medical resource utilisation in patients with severe allergic asthma in an Italian real-life setting
G. Canonica (Milan, Italy)
| |
Omalizumab in severe allergic asthma: a 4-year real world experience, Fife, Scotland
D. Dhasmana (St Andrews, United Kingdom)
| |
Patients’ perception of allergic asthma and their compliance to omalizumab in an Italian clinical setting
| |
Effects of Omalizumab treatment on nasal symptoms (SNOT score) in patients treated for severe asthma.
D. Robinson (LONDON, United Kingdom)
| |
How effective are oral steroids in asthma action plans?
T. Lim (Singapore, Singapore)
| |
Long term effect of Omalizumab on severe asthma
M. Bellocchia (TORINO, TO, Italy)
| |
Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
R. Shrimanker (Bristol, United Kingdom)
| |
Longitudinal modeling of prebronchodilator FEV1 response to benralizumab for patients with severe asthma
L. Roskos (Gaithersburg, United States of America)
| |
Monitoring of steroid-induced side-effects in a severe asthma service
G. Jones (Ellesmere Port, United Kingdom)
| |
A longitudinal follow-up of severe asthma patients receiving reslizumab
P. Chanez (Marseille, France)
| |
Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
R. Shrimanker (Bristol, United Kingdom)
| |
Follow-up of patients with severe asthma receiving reslizumab: an FEV1 analysis
J. Maspero (Buenos Aires, Argentina)
| |
Asthma control and exacerbation rate with omalizumab in Italian patients with severe allergic asthma: PROXIMA study
C. Bucca (Torino, To, Italy)
| |
Three years follow up after injection omalizumab therapy
D. Bhattacharyya (Delhi (New Delhi), India)
| |
Is it possible to predict asthma outcomes? A disease model for economic analysis.
L. Alvares (Basel, Switzerland)
| |
Seasonality of asthma exacerbations: efficacy of fluticasone furoate/vilanterol 100/25µg (FF/VI) vs fluticasone furoate 100µg (FF) alone
C. Crim (Research Triangle Park, United States of America)
| |
Effect of CYP3A4 inhibitors verapamil and itraconazole on the pharmacokinetics of AZD7986, an oral DPP1 inhibitor
J. Mäenpää (Mölndal, Sweden)
| |